Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

Chris D. Poole,Mark P. Connolly,Jane Chang,Craig John Currie

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

2015

Chris D. Poole
Mark P. Connolly
Jane Chang
Craig John Currie

Background In this analysis we report patients with advanced gastrointestinal stromal tumors (GIST) refractory to imatinib and sunitinib therapy as derived from the EuroQol-5D (EQ-5D) for progression-free (PF) and progressive disease health status.

Keywords:

Medicine
Pathology
Refractory
GiST
Placebo
Stromal cell
Regorafenib
Progressive disease
Imatinib
Sunitinib
imatinib mesylate
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations